4.5 Article

3-(7-Azaindolyl)-4-indolylmaleimides as a novel class of mutant isocitrate dehydrogenase-1 inhibitors: Design, synthesis, and biological evaluation

期刊

ARCHIV DER PHARMAZIE
卷 351, 期 10, 页码 -

出版社

WILEY-V C H VERLAG GMBH
DOI: 10.1002/ardp.201800039

关键词

2-hydroxyglutaric acid; 3-(7-azaindoyl)-4-indolylmaleimides; isocitrate dehydrogenase 1 inhibitors; tumor

资金

  1. China Postdoctoral Science Foundation [2014M550256]
  2. Strategic Priority Research Program of the Chinese Academy of Sciences [XDA12020328]
  3. Open Fund of State Key Laboratory of New Drugs, Shanghai Institute of Materia Medica, Chinese Academy of Sciences [SIMM1601KF-04]
  4. Personalized Medicines-Molecular Signature-Based Drug Discovery and Development
  5. Natural Science Foundation of Zhejiang Province [LY18H300009]
  6. National Natural Science Foundation of China [8150131067]

向作者/读者索取更多资源

A series of 3-(7-azainodyl)-4-indolylmaleimides was designed, synthesized, and evaluated for their isocitrate dehydrogenase 1 (IDH1)/R132H inhibitory activities. Many compounds such as 11a, 11c, 11e, 11g, and 11s exhibited favorable inhibitory effects on IDH1/R132H and were highly selective against the wild-type IDH1. Evaluation of the biological activities at the cellular level showed that compounds 11a, 11c, 11e, 11g, and 11s could effectively suppress the production of 2-hydroxyglutaric acid in U87MG cells expressing IDH1/R132H. Preliminary structure-activity relationship (SAR) and molecular modeling studies were discussed based on the experimental data obtained. These findings may provide new insights into the development of novel IDH1/R132H inhibitors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据